Citations

Clear

36 citation(s) found for "Suarez, Maria L G".

A Disease-Agnostic Nasal Microbiome Wellness Index for Standardized Assessment of Upper-Airway Respiratory Health
Barrera-Suarez, Maria A., Gupta, Vinod K. , Zhao, Xiaowei, Koller, Adam L, Zhao, Conan , Karnatovskaia, Lioudmila V. , Sung, Jaeyun , Sung, Jaeyun , Suh, Gina A. , O’Brien, Erin K. , Kronzer, Vanessa L.

Mayo Clinic

No container title available | July 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.07.19.739383 Get It

Abstract Background Upper-airway and respiratory conditions impose a large and growing global burden, yet there is no standardized way to assess whether a nasal microbiome is “healthy”. Currently, monitoring remains reactive, beginning only after symptoms manifest. The nasal cavity is well suited to proactive monitoring: it shapes respiratory health and pathogen colonization resistance, and can be sampled non-invasively and repeatedly. To address this gap, we introduce the Nasal Microbiome Wellness Index (NMWI), a disease-agnostic, continuous score of nasal microbiome health derived from LASSO-penalized logistic regression. Rather than counting taxa, it learns which taxa (and in what balance) characterize a healthy nose and returns the predicted log-odds that a profile resembles a healthy state. The index was trained on 1654 nasal 16S rRNA gene amplicon sequencing samples (589 healthy, 1065 non-healthy) pooled from 27 publicly available studies, uniformly reprocessed through a single computational pipeline. Results The NMWI comprises an interpretable signature of 24 taxa whose combined relative abundances determine the health-associated log-odds. Health-associated genera such as Corynebacterium and Cutibacterium raised the score, while dysbiosis-associated genera such as Pseudomonas and Escherichia – Shigella lowered it. The NMWI substantially outperformed the Shannon, Simpson, and Chao1 diversity indices, which showed negligible, directionally inconsistent separation between healthy and non-healthy samples (|Cliff’s δ | = 0.01–0.20), whereas the NMWI produced large, consistent separation ( δ = 0.65). It achieved a balanced accuracy of 74.37% on the training data (resubstitution estimate), and 73.43% under repeated 10-times 10-fold cross-validation. Performance remained stable at mean balanced accuracy of 73.82% under a leave-one-study-out framework, reflecting cross-study generalizability. In independent external cohorts, the balanced accuracy was 71.49%, and leave-one-disease-out analysis (in which each disease condition was withheld from training) showed a mean balanced accuracy of 63.92% across unseen conditions, consistent with a disease-agnostic design. The index also generalized across heterogeneous datasets spanning multiple 16S rRNA gene hypervariable regions—to our knowledge the first demonstration of such cross-study, cross-region transferability for the nasal cavity. Conclusions The NMWI distills a complex nasal microbial profile into a single interpretable score computed directly from the 16S rRNA gene data that dominate existing nasal research, making it immediately applicable to published and future datasets without re-sequencing. By replacing descriptive, diversity-based comparison with a quantitative standard, it offers a reproducible, open-source foundation for cross-study benchmarking, individual-level phenotyping, and longitudinal respiratory wellness monitoring.
Precision nutrition through diet-gut microbiome interactions: Emerging insights driven by artificial intelligence, microbiome health metrics, and mechanistic modeling
Barrera-Suarez, Maria A., Zhao, Conan , Karnatovskaia, Lioudmila V. , Sung, Jaeyun , Zhao, Conan Y, Sung, Jaeyun

Mayo Clinic

Gut Microbes Reports | March 31, 2026 | Volume: 3 | Issue: 1 | Pages: No page available

10.1080/29933935.2026.2650247 | PMID 41939240 Get It

SGLT2 Inhibitors Associated With Improved Kidney Function in Lithium‐Treated Patients With Mood Disorders: A Real‐World Historical Cohort Study
Tarikogullari, Idil , Pazdernik, Vanessa K., Suarez, Maria L. Gonzalez, Baweja, Raman , Miola, A., Leung, Jonathan G. , McElroy, Susan L, Cuellar-Barboza, Alfredo B, Gitlin, Michael , Ozerdem, A., Frye, M A, Singh, Balwinder, Miola, Alessandro , Leung, Jonathan G , Frye, Mark , Singh, Balwinder , Ercis, Mete , Miola, Alessandro , Abulseoud, Osama A. , McElroy, Susan L. , Cuéllar‐Barboza, Alfredo B. , Ozerdem, Aysegul, Frye, Mark A. , Singh, Balwinder

Mayo Clinic

Bipolar Disorders | March 8, 2026 | Volume: 28 | Issue: 2 | Pages: No page available

10.1111/bdi.70094 | PMID 41757872 Get It

ABSTRACT Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i), initially developed for type 2 diabetes, have shown promise in improving renal outcomes in patients with and without diabetes. However, their effect on lithium‐associated kidney dysfunction remains unknown. Methods This historical cohort study included patients from Mayo Clinic (2001–2023) with mood disorders who received lithium for ≥ 6 months and later used SGLT2i for ≥ 1 month. Data on SGLT2i use and lithium treatment were extracted from electronic health records. Serum creatinine values were used to calculate estimated glomerular filtration rate (eGFR) trajectories. Linear mixed‐effects models with piecewise linear splines were used to estimate eGFR slopes before and after SGLT2i initiation, adjusted for age and sex. Results Fifty‐six patients (mean age 57.4 years, 46.4% female), predominantly with bipolar disorder (87.5%), were included. The mean eGFR, measured nearest to SGLT2i initiation, was 77.9 ± 26.0 mL/min/1.73 m 2 , and the mean duration of SGLT2i use was 19.5 ± 17.8 months. Before SGLT2i initiation, eGFR declined at a rate of −1.43 mL/min/1.73 m 2 per year ( p < 0.001). After initiation, eGFR increased by 0.69 mL/min/1.73 m 2 per year, reflecting a + 2.13 change ( p = 0.025). Sensitivity analyses, including only patients on lithium at SGLT2i initiation ( n = 22) or who had > 1 year of SGLT2i use ( n = 29) showed similar, though non‐significant, changes in slopes. Conclusion SGLT2i treatment was associated with a significant improvement in eGFR trajectory in patients with mood disorders who received long‐term lithium therapy. These findings suggest a potential role for SGLT2is in mitigating lithium‐associated kidney dysfunction and highlight the need for randomized controlled trials in this population.
Sodium-glucose cotransporter-2 inhibitors lower risk of kidney replacement therapy and mortality in bipolar disorder with chronic kidney disease
Singh, Balwinder, Suarez, Maria L. Gonzalez, Baweja, Ritika, Abulseoud, Osama A. , Saunders, Erika F.H., Frye, Mark A., Baweja, Raman , Singh, Balwinder , Singh, Balwinder , Abulseoud, Osama A , Baweja, Ritika , Saunders, Erika F.H. , Frye, Mark A.

Mayo Clinic

Therapeutic Advances in Psychopharmacology | February 20, 2026 | Volume: 16 | Issue: No issue available | Pages: No page available

10.1177/20451253261423437 | PMID 41732711 Get It

Background: Bipolar disorder (BD) is associated with a higher prevalence of chronic kidney disease (CKD) and increased mortality, yet individuals with both BD and CKD are less likely to receive kidney replacement therapy (KRT). Sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide renal protection in diabetes, but their long-term effects in this high-risk population remain unknown. Objectives: To evaluate whether SGLT2i use reduces the risk of KRT and all-cause mortality in adults with BD and mild-to-moderate CKD (stage ⩽ 3). Design: Observational cohort study with propensity score matching (PSM). Method: In this study using TriNetX (2009–2024) real-world database, 89,369 adults with BD and mild-to-moderate CKD were classified as SGLT2i users ( n = 12,736) or nonusers ( n = 76,633). Primary outcomes were progression to KRT and all-cause mortality over 5 years. Adjusted hazard ratios (aHRs) were estimated using Cox proportional hazards models, and 1:1 PSM reduced confounding. Subgroup analyses examined sex, race/ethnicity, diabetes status, CKD stage, and mood stabilizer use. Results: SGLT2i use was associated with lower risk of KRT (aHR 0.47 (95% CI, 0.42–0.53)) and all-cause mortality (aHR 0.69 (95% CI, 0.65–0.73); both p < 0.001). Protective effects were consistent across subgroups, including individuals receiving lithium, lamotrigine, valproate, or antipsychotics. After PSM (10,967 matched pairs), 5-year KRT-free survival was 94.61% versus 90.99%, and overall survival was 78.67% versus 67.53% (both p < 0.001). Given the observational design, the possibility of residual or unmeasured confounding canot be excluded. Conclusion: SGLT2i therapy in individuals with BD and mild-to-moderate CKD is associated with substantially lower risks of KRT and all-cause mortality. Prospective trials are needed to confirm these findings.
Resistant Hypertension: Integration of Novel Agents and Interventional Approaches in Clinical Practice
Arriola‐Montenegro, Jose , Chapoñan-Lavalle, Andres , Nombera-Aznaran, Natalia , Abdalla, Mohammed S., Bizer, Benjamin , Mohan, A. , Verdugo, Irma Andrea Muñoz , Zardoost, Pooya , Ordaya-Gonzales, Karina , Rizzo, Alan Villarreal , Rios-García, Wagner , Yip, Laverne Kar Yin, Suarez, Maria L. Gonzalez, Abdalla, Mohammed , Mohan, Arjunmohan , Muñoz Verdugo, Irma Andrea , Villarreal Rizzo, Alan F , Gonzalez Suarez, Maria L

Mayo Clinic

Reviews in Cardiovascular Medicine | January 29, 2026 | Volume: 27 | Issue: 1 | Pages: No page available

10.31083/rcm45429 | PMID 41659095 Get It

Resistant hypertension (RH) is a high-risk phenotype characterized by blood pressure readings ≥130/80 mmHg despite maximally tolerated therapy with three antihypertensive agents, including a diuretic, or controlled blood pressure requiring four or more medications. The diagnosis of RH requires a structured evaluation that confirms accurate blood pressure measurement, excludes pseudoresistance—particularly nonadherence and white coat hypertension—and identifies secondary causes such as obstructive sleep apnea, primary aldosteronism, renovascular disease, pheochromocytoma, and Cushing syndrome. RH arises from overlapping mechanisms, including activation of the renin–angiotensin–aldosterone system (RAAS), sympathetic overactivity, arterial stiffness, volume expansion, and immune-mediated pathways. Management begins with lifestyle modification and optimized triple therapy, followed by mineralocorticoid receptor antagonists as the preferred fourth-line treatment. Emerging pharmacological options, such as sodium–glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists, endothelin receptor antagonists, aldosterone synthase inhibitors, and angiotensin receptor and neprilysin inhibitors (ARNIs), offer additional therapeutic potential; meanwhile, device-based interventions, including renal denervation and baroreflex activation therapy, have shown sustained blood pressure reductions in selected patients. Future directions highlight precision medicine, digital health technologies, and artificial intelligence as methods to improve diagnosis, guide individualized therapy, and enhance long-term blood pressure control.
Gastrointestinal Bleeding Due to Angiodysplasia in Patients with CKD
Suarez, Maria Lourdes Gonzalez , Gonzalez Suarez, Maria L

Mayo Clinic

Kidney360 | October 30, 2025 | Volume: 6 | Issue: 10 | Pages: 1641-1642

10.34067/kid.0000000994 | PMID 41166074 Get It

Abstract FR435: Artificial Intelligence-Enhanced Electrocardiography for the Detection and Prediction of Arterial Hypertension: A Systematic Review
Baez, Daniel Banegas, Silva-Jiménez, Sashenka , Torres, Abigail Via y Rada, Narváes, Doménica, Quintana, Lynn, Rios-Garcia, Alondra A. , Baez, Daniel Banegas, Rios-García, Wagner , Torres, Abigail Via y Rada, Quintana, Lynn, Arriola‐Montenegro, Jose , Suarez, Maria Lourdes Gonzalez

Mayo Clinic

Hypertension | October 16, 2025 | Volume: 82 | Issue: Suppl_1 | Pages: No page available

10.1161/hyp.82.suppl_1.fr435 Get It

Background: Early detection and prediction of arterial hypertension (HTN) are vital to reduce cardiovascular morbidity and mortality. AI has enhanced ECG diagnostic capabilities, enabling detection of latent cardiovascular abnormalities. Aims: This systematic review evaluates current evidence on AI-enhanced ECG for detection and prediction of HTN in in both clinical and subclinical populations. Methods: A search was conducted on April 28, 2025, in PubMed, Scopus, and Web of Science. Gray literature and study reference lists, plus the first 10 pages of Google Scholar, were screened. The review followed PRISMA 2020 guidelines. Bias risk was assessed using PROBAST (for prediction models) and QUADAS-2 (for diagnostic studies). Two reviewers independently performed study selection and data extraction after pilot training. Results: A total of 26 studies were included: 16 focused on detection and 10 on prediction of HTN using AI-enhanced ECG. Overall, 96% reported successful outcomes, underscoring the strong diagnostic and prognostic potential of this approach. Among detection studies, 94% successfully identified hypertensive individuals, classified blood pressure (BP) levels, or evaluated cardiovascular risk. Most were retrospective in design (75%), with internal validation in 44% and external validation in 19%. Sample sizes ranged from 100 to over 120,000, including healthy and cardiovascular patients. Commonly used algorithms included deep Learning, random forest, and ensemble methods, often using single-lead ECG data, highlighting the feasibility of wearable technologies. QUADAS-2 identified 56% of studies had low risk of bias. All prediction studies achieved accurate estimation of systolic/diastolic BP or predicted future HTN onset. Designs were 40% experimental and 50% retrospective. All studies reported internal validation, and 50% included external validation. AI models such as CNNs, ResNet-LSTM, and U-Net were used across clinical and community-based populations, with follow-up periods of up to 6.8 years. Populations were predominantly normotensive or mixed. PROBAST assessments showed 60% low and 40% moderate risk of bias. Conclusion: AI-enhanced ECG is a promising, non-invasive tool for early detection and prediction of HTN. However, external validation and clinical trials are needed to support integration and generalizability.
Navigating the Complexities of Cancer Treatment-Induced Hypertension
Arriola‐Montenegro, Jose , Roth, John , Suarez, Maria Lourdes Gonzalez , Gonzalez Suarez, Maria L , Roth, John

Mayo Clinic

Journal of Cardiovascular Development and Disease | June 19, 2025 | Volume: 12 | Issue: 6 | Pages: 235

10.3390/jcdd12060235 | PMID 40558670 Get It

Cancer therapy-induced hypertension (HTN) is an increasingly recognized complication associated with a wide range of anticancer agents, including vascular endothelial growth factor (VEGF) inhibitors, proteasome inhibitors, tyrosine kinase inhibitors, and alkylating agents. The pathogenesis of HTN in this setting is multifactorial, involving mechanisms such as endothelial dysfunction, nitric oxide (NO) suppression, sympathetic nervous system activation, and vascular remodeling. Additional factors, including paraneoplastic syndromes, poorly controlled pain, mood disturbances, and overlapping cardiovascular risk factors like obesity and diabetes, further contribute to the complexity of diagnosis and management. Despite its prevalence and clinical implications, cancer therapy-induced HTN is often addressed using general population guidelines, with limited oncology-specific protocols available. Accurate blood pressure measurement and individualized treatment plans are critical to optimize outcomes and avoid interruptions to cancer therapy. Antihypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and calcium channel blockers have shown efficacy in both blood pressure control and, in some cases, oncologic outcomes. A multidisciplinary approach involving oncologists, cardiologists, and primary care providers is essential to navigate the interplay between cancer treatment and cardiovascular health. Ongoing research is needed to develop targeted guidelines and improve the long-term care of cancer patients affected by treatment-induced HTN.
Impact of Aging and Cellular Senescence in the Pathophysiology of Preeclampsia
Kattah, Andrea G. , Gojković, Tamara , Pruett, Jacob E. , Jayachandran, Muthuvel , Sousa, Círia, Santos, Janelle, Hassan, Coline Abou, Gonzales‐Suarez, Maria, Šuvakov, Sonja , Enninga, Elizabeth Ann L. , Garovic, Vesna D.

Mayo Clinic

Comprehensive Physiology | April 3, 2025 | Volume: 13 | Issue: 4 | Pages: 5077-5114

10.1002/j.2040-4603.2023.tb00282.x Get It

Abstract The incidence of hypertensive disorders of pregnancy is increasing, which may be due to several factors, including an increased age at pregnancy and more comorbid health conditions during reproductive years. Preeclampsia, the most severe hypertensive disorder of pregnancy, has been associated with an increased risk of future disease, including cardiovascular and kidney diseases. Cellular senescence, the process of cell cycle arrest in response to many physiologic and maladaptive stimuli, may play an important role in the pathogenesis of preeclampsia and provide a mechanistic link to future disease. In this article, we will discuss the pathophysiology of preeclampsia, the many mechanisms of cellular senescence, evidence for the involvement of senescence in the development of preeclampsia, as well as evidence that cellular senescence may link preeclampsia to the risk of future disease. Lastly, we will explore how a better understanding of the role of cellular senescence in preeclampsia may lead to therapeutic trials. © 2023 American Physiological Society. Compr Physiol 13:5077‐5114, 2023.
Effect of an Interdisciplinary CKD Clinic on Disease Progression, Health Care Use, and Social Determinants of Health
Chavez, Maria Mateo , Moran-Melendez, Andrea, Salter, Lucy , Vaughan, Lisa E. , Loor-Torres, Ricardo , Albright, Robert C. , Manohar, Sandhya , Zoghby, Ziad , Kattah, Andrea G. , Suarez, Maria Lourdes Gonzalez , Hines, Vicky L., Gonzalez, Daniel A , Bandi, Satya Sai Sri, Boehmer, Kasey R. , Mateo Chavez, Maria B , Vaughan, Lisa , Loor-Torres, Ricardo J , Albright, Robert, Kattah, Andrea G , Gonzalez Suarez, Maria L , Rose, Katie, Hines, Vicky , Gonzalez-Mosquera, Daniel A , Bandi, Satya Sri , Boehmer, Kasey R , El-Zoghby, Ziad , Salter, Lucy , Rose, Katie

Mayo Clinic

Kidney360 | February 18, 2025 | Volume: 6 | Issue: 6 | Pages: 937-946

10.34067/kid.0000000734 | PMID 39964760 Get It

Key Points Patient-centered care in an interdisciplinary CKD clinic addresses complex needs and supports comprehensive CKD management. Implementation of an interdisciplinary CKD clinic reduced hospital admissions by 26%, emergency department visits by 30%, and increased nephrology consultations. Comprehensive care models with integrated registries enhance tailored interventions, leading to improved CKD management outcomes. Background CKD is a significant public health issue globally. Its progressive nature calls for innovative care models to mitigate disease progression and enhance patient outcomes. An interdisciplinary clinic model may offer comprehensive care tailored to the needs of patients with CKD. The aim of this study was to evaluate the effect of an interdisciplinary CKD clinic on disease progression, health care utilization, and social determinants of health (SDOH). Methods We conducted a retrospective cohort study at the Mayo Clinic in Rochester, Minnesota. The study included 534 patients enrolled in the CKD clinic between March 5, 2021, and May 31, 2022, excluding those who opted out of research. The intervention involved a clinical registry and an interdisciplinary team delivering evidence-based care pathways, patient education, shared decision making, and care coordination. The primary outcomes assessed were CKD progression and health care utilization, while secondary outcomes examined the effect of SDOH. Results At entry, the median age was 73 (interquartile range, 64–79) years, with 60% at stage 4 or lower. Clinic implementation correlated with a 26% decrease in hospital admissions (incidence rate ratio [IRR], 0.74; 95% confidence interval [CI], 0.60 to 0.91; P = 0.004) and a 30% reduction in emergency visits (IRR, 0.70; 95% CI, 0.57 to 0.87; P = 0.001). Nephrology consultations increased by 46% (IRR, 1.46; 95% CI, 1.34 to 1.60; P < 0.001), reflecting enhanced specialized care. Lower exercise frequency and unemployment were linked to increased CKD progression and health care usage. Conclusions An interdisciplinary CKD clinic supported by a registry can potentially reduce health care utilization among patients with CKD, with SDOH playing a critical role in disease management.